Navigation Links
Drug Reduces Airway Mucus in Preclinical Asthma Model
Date:2/19/2008

tial" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD

bill@inverseon.com

http://www.inverseon.com

(212) 222-1188

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Landfill mining reduces environmental impact of growing waste
2. Landfill mining reduces environmental impact of growing waste
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
5. Heavier hydrogen on the atomic scale reduces friction
6. Genmab Announces Encouraging Preclinical Data for ofatumumab
7. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
8. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach 2Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach 3Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach 4Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach 5Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach 6Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach 7PFGE Analysis of Chromosomal DNA From a Single Hair Root 2Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 2Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 3Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 4
Breaking Biology News(10 mins):University of the Basque Country research on plankton at Urdaibai 2CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2ADA releases updated position paper on nutrient supplementation 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 1SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13357 13CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 1CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 2CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 3CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients 53611 4Connectyx Partners with InstantAmber a Leader in Child Safety and Missing Children Awareness 53606 1Connectyx Partners with InstantAmber a Leader in Child Safety and Missing Children Awareness 53606 2Connectyx Partners with InstantAmber a Leader in Child Safety and Missing Children Awareness 53606 3